Literature DB >> 10836015

Childhood tumors.

J M Herrera1, A Krebs, P Harris, F Barriga.   

Abstract

Pediatric solid tumors represent a distinct set of malignancies of embryonal origin whose incidence peaks in the first years of life. Specific genetic anomalies with pathogenic significance, which have helped to define the diagnosis better and to improve the prognosis of children with these tumors, recently have been discovered. Survival of children with solid tumors also has improved significantly because of effective multidisciplinary care, which, in this case, always involves chemotherapy and surgery. These favorable results require that children with these diseases are referred and treated at institutions that have multidisciplinary teams and the infrastructure and expertise for caring for these children. Diagnostic and therapeutic principles for the most common childhood solid tumors are discussed in this article, with an emphasis on surgical procedures.

Entities:  

Mesh:

Year:  2000        PMID: 10836015     DOI: 10.1016/s0039-6109(05)70210-3

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  3 in total

Review 1.  Management of stage I cervical sarcoma botryoides in childhood and adolescence.

Authors:  Susanne E M Gruessner; Charles O A Omwandho; Thomas Dreyer; Renate Blütters-Sawatzki; Alfred Reiter; Hans R Tinneberg; Rainer M Bohle
Journal:  Eur J Pediatr       Date:  2004-06-02       Impact factor: 3.183

2.  A successful pregnancy during the treatment of cervical sarcoma botryoides and advantage of fertility sparing management: A case report.

Authors:  Selçuk Ayas; Lutfiye Uygur; Evrim Bostanci; Ayşe Gürbüz
Journal:  Iran J Reprod Med       Date:  2015-02

3.  Novel targeted therapy for neuroblastoma: silencing the MXD3 gene using siRNA.

Authors:  Connie Duong; Sakiko Yoshida; Cathy Chen; Gustavo Barisone; Elva Diaz; Yueju Li; Laurel Beckett; Jong Chung; Reuben Antony; Jan Nolta; Nitin Nitin; Noriko Satake
Journal:  Pediatr Res       Date:  2017-05-31       Impact factor: 3.756

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.